- Conditions
- Tetanus, Diphtheria, Pertussis, Measles, Polio
- Interventions
- Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 3,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 40
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine Clear all
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Tetanus, Diphtheria, Pertussis
- Interventions
- Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 15 Years to 69 Years
- Enrollment
- 545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
- Conditions
- Pregnancy
- Interventions
- Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Interventions
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 4,209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
- Conditions
- Meningococcal Meningitis
- Interventions
- Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fremont, California • Madera, California + 14 more
- Conditions
- Diphtheria, Tetanus, Pertussis
- Interventions
- DAPTACEL®: DTaP
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 649 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
- Conditions
- Tetanus, Diphtheria, Pertussis
- Interventions
- Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 10 Years to 11 Years
- Enrollment
- 1,302 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
- Conditions
- Meningococcal Disease
- Interventions
- MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
- Biological · Drug · Other
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pertussis
- Interventions
- TDAP
- Biological
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 375 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Nashville, Tennessee
- Conditions
- Tetanus, Diphtheria and Acellular Pertussis Vaccination
- Interventions
- Tdap
- Biological
- Lead sponsor
- ABO Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Glassboro, New Jersey
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Interventions
- Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 1,363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more
- Conditions
- Hepatitis A
- Interventions
- Havrix™, Infanrix™, ActHIB™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 13 Months
- Enrollment
- 468 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
- Conditions
- Prolonged Apnea, Prolonged Bradycardia
- Interventions
- Infanrix, Pediatrix
- Biological
- Lead sponsor
- American SIDS Institute
- Other
- Eligibility
- 56 Days to 60 Days
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 10
- States / cities
- Austell, Georgia • Marietta, Georgia • Belle Mead, New Jersey + 6 more